Why global pharma companies choose India for GCCs
BioSpectrum Asia|August 2024
India’s pharmaceutical industry is globally recognised for its capabilities in research and manufacturing and for its skilled labour. The country’s attractiveness as a destination for Global Capability Centres GCCs) is underpinned by several key factors, including cost-efficiency, a vast talent pool, robust infrastructure, and strong regulatory support.
Anil Matai
Why global pharma companies choose India for GCCs

India serves as a key global hub for development, attracting investments of more than $7 billion. Global pharmaceutical companies have established GCCs in India which serve as centres of excellence for drug discovery, formulation development, and healthcare solutions, while also supporting a strong ecosystem by employing talent and increasing the knowledge base.

For instance, Novartis has had a significant footprint in India since 1947, and in the last two decades, it has evolved to be an integral part of the development journey of many breakthrough medicines in various therapeutic areas like cardiovascular, oncology, immunology, neurology, and ophthalmology, amongst others. Similarly, MSD is primed to support the Indian government in protecting every woman through HPV vaccination with nearly 85 per cent of their products being manufactured locally. In India, Novo Nordisk is conducting phase 2-4 clinical trials across major disease areas with over 3,000 enrolled patients. With 37 ongoing trials in various therapy areas, India accounts for 7-8 per cent of Novo Nordisk's global patient pool. As GCCs have evolved to become centres for innovation and research, India has transformed into a hub for new product development for global enterprises. Consequently, over 50 per cent of the world's GCCs are now located in India, driven by factors that provide a competitive edge for businesses aiming to optimise operations and drive innovation.

Cost-efficiency of conducting business

India offers a compelling cost-quality ratio, making it financially advantageous for companies to establish their GCCs in the country. Labour costs in India are significantly lower than those in countries like North America and Europe, enabling companies to reduce operational expenses while maintaining profitability.

Esta historia es de la edición August 2024 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición August 2024 de BioSpectrum Asia.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE BIOSPECTRUM ASIAVer todo
"We are dedicated to helping people of all ages see brilliantly"
BioSpectrum Asia

"We are dedicated to helping people of all ages see brilliantly"

The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.

time-read
5 minutos  |
BioSpectrum Asia Jan 2025
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
BioSpectrum Asia

Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation

In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.

time-read
6 minutos  |
BioSpectrum Asia Jan 2025
Building the Future of Medicine
BioSpectrum Asia

Building the Future of Medicine

PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical

time-read
4 minutos  |
BioSpectrum Asia Jan 2025
Emerging Leader in Cell & Gene Therapy
BioSpectrum Asia

Emerging Leader in Cell & Gene Therapy

STARTUP OF THE YEAR 2024 - ImmunoACT

time-read
3 minutos  |
BioSpectrum Asia Jan 2025
Improving Access for Respiratory Healthcare
BioSpectrum Asia

Improving Access for Respiratory Healthcare

STARTUP OF THE YEAR 2024 - Aevice Health

time-read
4 minutos  |
BioSpectrum Asia Jan 2025
Making an Impact with a 'CliKX'
BioSpectrum Asia

Making an Impact with a 'CliKX'

Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ

time-read
4 minutos  |
BioSpectrum Asia Jan 2025
Eyeing 20-20 Vision of Excellence
BioSpectrum Asia

Eyeing 20-20 Vision of Excellence

Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research

time-read
4 minutos  |
BioSpectrum Asia Jan 2025
Refining the Use of Radiation
BioSpectrum Asia

Refining the Use of Radiation

Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals

time-read
3 minutos  |
BioSpectrum Asia Jan 2025
Honouring Innovators in Asia's Thriving Life Sciences Sector
BioSpectrum Asia

Honouring Innovators in Asia's Thriving Life Sciences Sector

Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.

time-read
2 minutos  |
BioSpectrum Asia Jan 2025
How To Control Indian Diabetes Growth
BioSpectrum Asia

How To Control Indian Diabetes Growth

World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.

time-read
4 minutos  |
December 2024